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Summary
Background—The Boston Area Travel Medicine Network surveyed travelers on travel-related 
health problems.
Methods—Travelers were recruited 2009–2011 during pre-travel consultation at three clinics. 
The investigation included pre-travel data, weekly during-travel diaries, and a post-travel 
questionnaire. We analyzed demographics, trip characteristics, health problems experienced, and 
assessed the relationship between influenza vaccination, influenza prevention advice, and 
respiratory symptoms.
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Results—Of 987 enrolled travelers, 628 (64%) completed all surveys, of which 400 (64%) 
reported health problems during and/or after travel; median trip duration was 12 days. Diarrhea 
affected the most people during travel (172) while runny/stuffy nose affected the most people after 
travel (95). Of those with health problems during travel, 25% stopped or altered plans; 1% were 
hospitalized. After travel, 21% stopped planned activities, 23% sought physician or other health 
advice; one traveler was hospitalized. Travelers who received influenza vaccination and influenza 
prevention advice had lower rates of respiratory symptoms than those that received influenza 
prevention advice alone (18% vs 28%, P = 0.03).
Conclusions—A large proportion of Boston-area travelers reported health problems despite pre-
travel consultation, resulting in inconveniences. The combination of influenza prevention advice 
and influenza immunization was associated with fewer respiratory symptoms than those who 
received influenza prevention advice alone.
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Travel; Influenza; Travel-associated health problems; Survey; Knowledge-attitudes-practices
1. Introduction
Global travel continues to grow, with international tourist arrivals reaching 1.1 billion in 
2014 [1]. With increasing international travel, the number of travelers becoming ill during or 
after travel could also increase.
Over the past three decades, several studies have evaluated health issues encountered during 
and after travel. These include a survey of Swiss travelers and one of American travelers 
whose trips were up to 3 months, and analyses from GeoSentinel, a worldwide network of 
specialized tropical and travel medicine clinics that collect data on travel-related illnesses 
[2–5]. Health problems occurred during 15% of journeys undertaken by 10,524 Swiss short-
term travelers surveyed from 1981 to 1984; 8% consulted a doctor and 3% were unable to 
work for an average of 15 days [2]. A survey of U.S. travelers found that 64% of 784 
reported a health problem, particularly those who undertook longer trips; 8% needed 
medical evaluations and 26% were ill after return [3]. Two GeoSentinel analyses that 
examined 17,353 ill returned travelers seen from 1996 to 2004 and 42,173 ill returned 
travelers seen from 2007 to 2011 found the most commonly reported disorders were 
gastrointestinal, systemic febrile illness, dermatologic, and respiratory problems [4,5]. In the 
latter study, 41% of travelers sought pre-travel medical consultations [5].
Pre-travel medical consultations are recommended by the medical community, national 
agencies such as the U.S. Centers for Disease Control and Prevention (CDC), and 
professional organizations such as the International Society of Travel Medicine to prepare 
travelers on how to prevent or manage health problems associated with travel. However, 
airport-based surveys of outbound U.S. travelers conducted in 2003 and 2009 found that 
only about 36–54% of travelers to low- or low-middle-income countries had sought health 
information [6,7].
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1.1. Study objectives
Given increased international travel, changes in traveling populations, the evolving risk of 
disease, and ubiquitous infections like influenza, there is a need to re-evaluate the 
occurrence of illness associated with travel and to use the results to inform health 
recommendations. In international travelers attending pre-travel health consultations in three 
Boston-area travel medicine clinics, we sought to: 1) describe the types, frequency, and 
impact of health problems occurring during and after travel; 2) assess possible associations 
of underlying health conditions and trip characteristics with travel-related health problems; 
and 3) assess the association of influenza vaccination and pre-travel health advice with 
respect to travel-associated respiratory symptoms, because respiratory infections are among 
the most common health problems that travelers encounter [2–5] and influenza is the most 
common vaccine-preventable disease in travelers [8].
2. Materials and methods
2.1. Sample description
We recruited participants aged ≥18 years attending a pre-travel health consultation at three 
clinics: two in urban, academic hospitals and one in a suburban hospital in the Boston-Area 
Travel Medicine Network (BATMN) from 2009 through 2011. Written consent was obtained 
from all participants and Institutional Review Board (IRB) approvals obtained at all clinic 
sites.
2.2. Measures
At the pre-travel health consultation, travelers were invited to participate and were 
encouraged to complete a during-travel weekly diary for each week of travel and a post-
travel survey upon return. Information collected at baseline (pre-travel) included 
demographic and trip characteristics, underlying health conditions and medications, 
immunizations administered, medications prescribed pre-travel, and information received 
during the pre-travel health consultation. Underlying health conditions included diabetes 
mellitus, asthma, heart disease, HIV/AIDS, solid organ or bone marrow transplantation, 
cancer, autoimmune disease, pregnancy, and unspecified chronic medical conditions 
(including chronic kidney disease on dialysis, cirrhosis, and other diagnoses that did not fit 
into one of the above-mentioned categories). Specific immune suppressive or immune 
modulating medications, including prednisone or other steroids, ≥20 mg daily, methotrexate, 
cancer chemotherapy, and other immunosuppressive drugs were recorded. The during-travel 
weekly diary queried travel behaviors (including drinking tap water, eating salads, using 
insect repellent), illnesses experienced, and impact of illness (including needed medical 
evaluation, stopped activities, hospitalizations). The post-travel survey included questions 
about adherence to certain prevention practices, illnesses since return, and impact of those 
illnesses. Participants were included in the analysis if they completed the pre-travel baseline 
questionnaire, at least one during-travel weekly diary, and a post-travel survey 2–4 weeks 
after return. A unique numeric identifier was used to link the pre-travel baseline data to the 
during-travel and post-travel surveys.
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Because the study was conducted during the H1N1 outbreak, we assessed influenza advice 
and vaccination in the pre-travel setting. Respiratory symptoms assessed included cough, 
runny/stuffy nose, and sore throat. Influenza-like illness was defined according to the WHO 
definition of cough with fever; however, exact temperature data for travelers experiencing 
fever were not collected systematically.
2.3. Analysis
Data were entered into two separate password-protected databases (CS Pro, U.S. Census 
Bureau, Washington, DC), one for the pre-travel baseline data and a second for the during-
travel/post-travel surveys. Those who reported experiencing ≥1 symptom during or after 
travel were compared with those who did not report any symptoms. Travelers who reported a 
health problem both during and after travel were counted both in the analysis of health 
problems during travel as well as after travel. Travel destinations were grouped by the 2011 
UN human development index (if a traveler went to ≥1 country, the lowest ranked country 
was used) [9]. Demographic and travel characteristics were evaluated by chi-square test for 
categorical and Wilcoxon rank sum test for continuous variables. Results from bivariate 
analyses were expressed as prevalence rate ratios (PRR) with 95% confidence intervals. All 
two-tailed p-values <0.05 were considered statistically significant. SAS 9.2 (SAS Institute, 
Cary, NC) was used for all analyses.
3. Results
3.1. Sample description
We enrolled 987 travelers. Of those, 628 (64%) completed all three data collection 
instruments, including at least one during-travel weekly diary and a post-travel survey 2–4 
weeks after return (Fig. 1); sites differed in their travelers’ completion rates (39%–75%). 
Comparison of the 628 to the 359 who did not complete all three parts (non-completers) 
revealed no differences, except that white travelers had a higher rate of completion than all 
other racial/ethnic groups (P < 0.001) and completion rates were higher in older travelers 
(median age 47 years vs. 32 years in non-completers, P < 0.001).
3.2. Demographic and trip characteristics
Of the 628 travelers included in the analysis, 59% were female, with a median age of 47 
years (range 19–83 years). The median duration of travel was 12 days (range 3–65 days). 
Most of the 628 participants were U.S.-born, white, traveled for tourism/vacation, and stayed 
in hotels (Table 1). Non-whites were less likely to report health problems than whites (PRR 
= 0.83; 95% CI (0.68–1.01), P = 0.04).
The 10 most common destinations were India, South Africa, Tanzania, Kenya, Haiti, Peru, 
Thailand, Egypt, China, and Costa Rica; more travelers reported experiencing health 
problems in India, Tanzania, Peru, and Thailand (68% of travelers reporting health 
problems) compared to travelers to the other six countries (54% of travelers reporting health 
problems). A higher proportion of U.S.-born travelers reported a health problem than 
foreign-born travelers, although this was not statistically significant (P = 0.08).
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Nearly all (99%) of the 628 travelers reported receiving advice on food and water 
precautions and diarrhea management, and 333 (53%) reported receiving advice on 
influenza prevention. Among those with information regarding specific immunizations, 384 
(84%) of 412 with information about hepatitis A vaccine received the vaccine, 281 (78%) of 
361 with typhoid vaccine information received the vaccine (oral or injection), and 145 (46%) 
of 315 with influenza vaccine information received the vaccine.
3.3. Types, frequency, and impact of health problems occurring during and after travel
Of the 628 participants, 400 (64%) reported health problems during and/or after travel; 151 
(38%) of 400 reported health problems during travel only, 91 (23%) of 400 reported health 
problems after travel only, and 158 (39%) of 400 reported health problems both during and 
after travel. In total, 309 (77%) of 400 travelers reported health problems during travel and 
249 (62%) of 400 reported health problems after travel. The most common type of health 
problem was diarrhea, affecting 208 (52%) of 400 travelers (Table 2). One hundred thirty-
one travelers reported diarrhea during travel only (33% of those who reported health 
problems), 36 travelers reported diarrhea after travel only (9% of 400 travelers), and 41 
travelers reported diarrhea during and after travel (10% of 400 travelers). While diarrhea was 
the most commonly reported symptom during travel, runny/stuffy nose was the most 
common symptom reported after travel, followed by cough. Other frequently reported 
specific symptoms overall include headache, fatigue, nausea/vomiting, shaking chills, fever, 
constipation, myalgia, and rash (Table 2).
Of the 309 travelers who experienced illness during travel, 56 (18%) stopped planned 
activities and 23 (7%) had to change plans due to health problems (Fig. 2). Four travelers 
were hospitalized during travel, for a mean of 2.25 days (range 1–4 days); one reported 
having heart disease and was hospitalized for pulmonary embolism, while two others 
reported unspecified chronic medical conditions. Travelers who saw a doctor or sought 
medical advice from sources other than doctors (pharmacist/clinic staff/healer/friend) 
because of health problems during travel reported final diagnoses of infections, injury, 
allergic reaction, and drug reaction (Table 3).
Of 249 travelers who experienced illness after travel, 53 (21%) stopped planned activities, 
40 (16%) saw a doctor, 17 (7%) sought other medical advice because of travel-related health 
problems, and one traveler was hospitalized. Travelers who sought medical care by a 
healthcare professional after travel reported diagnoses that included infections, pulmonary 
embolism, asthma exacerbation, ectopic pregnancy, and dermatologic problems (Table 3).
3.4. Association of travel-related health problems with underlying health conditions or trip 
characteristics
Travelers experienced health problems whether they went to very high, high, medium, or 
low UN human development index (HDI) destinations (Table 1).
Less than half (41%) of 628 travelers reported either having pre-existing health conditions or 
taking medications on a regular basis. There was no difference in reported health problems 
in those with and without specific underlying health conditions (such as diabetes mellitus, 
asthma, heart disease, cancer, and autoimmune disorders). Also, there was no difference in 
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reported health problems in those who were taking medications prior to travel and those who 
were not (including prednisone, methotrexate, cancer chemotherapy, other 
immunosuppressive drugs) (P = 0.74). However, a higher proportion of travelers with an 
“unspecified chronic medical condition” reported health problems (31% vs 23% no problem; 
P = 0.03).
Median trip duration was 12–16 days for travelers with specific symptoms reported, except 
rash or other skin problems, for which median trip duration was 26 days (range 5–41 days). 
Median trip durations were 19–20 days for the symptoms of runny/stuffy nose and sore 
throat.
3.5. Respiratory illness and influenza vaccination
Respiratory symptoms, including cough, sore throat, or runny nose, were reported by 143 
(23%) of 628 travelers, affecting 36% of those who reported health problems. Twenty-three 
(16%) of the 143 with respiratory symptoms had cough and fever suggestive of influenza-
like illness (ILI). There was a progressive increase in proportions reporting respiratory 
symptoms with declining UN HDI (17% for high HDI, 31% for medium, 51% for low).
There were 204 travelers who received influenza vaccine before travel and influenza 
prevention advice at the pre-travel appointment. Of these, 36 (18%) reported at least one 
respiratory symptom during or after travel; 4 (2%) had cough and fever suggestive of ILI. Of 
129 travelers who received influenza prevention advice but did not receive influenza 
vaccination at the pre-travel appointment nor had previous vaccination for the current 
season, 36 (28%) experienced respiratory symptoms during and/or after travel; 10 (8%) 
experienced cough and fever suggestive of ILI. Of 41 travelers who did not receive influenza 
prevention advice, did not receive influenza vaccination at the pre-travel appointment, and 
did not have previous vaccination for the current season, 7 (17%) experienced respiratory 
symptoms during and/or after travel; none experienced cough and fever suggestive of ILI. 
Those who were vaccinated for influenza before travel and who received influenza 
prevention advice at the travel clinic visit had a lower rate of any respiratory symptoms 
during and/or after travel than those who received influenza prevention advice alone (18% vs 
28%, P = 0.03).
Age was the only characteristic that differed between travelers who were immunized and 
whose who were not immunized (Supplemental Table 4). Those who were immunized were 
older than those who were not immunized (median age 49 vs. 42 years; P = 0.0009). 
Travelers visiting friends and relatives (VFR) were vaccinated at a rate similar to non-VFR 
travelers (Supplemental Table 4). Among those who were vaccinated for influenza prior to 
travel, VFR travelers experienced any respiratory symptoms during or after travel at a rate 
similar to non-VFRs.
4. Discussion
A large proportion of our cohort of travelers experienced health problems during or after 
travel despite receiving pre-travel consultation, similar to a study of American travelers 
nearly two decades earlier [3]. Given the increase in U.S. annual outbound travel from 52 
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million to more than 68.2 million trips from 1995 to 2014 and the evidence from our study 
[10], morbidity from travel-related illness clearly affects a sizable population. Identifying 
health problems associated with travel and offering strategies to modify risks continue to be 
relevant. Despite providing travel advice through “traditional” travel clinic visits in the past 
three decades, travel-related illnesses remain prevalent and new approaches to prevent illness 
are needed.
The most common symptoms reported by our travelers (diarrhea, headache, cough/runny 
nose, myalgia/fatigue, fever/chills, and rash) were consistent with previous studies [2–5] as 
well as a recent survey of Finnish travelers [11]. Health problems led to changing or 
stopping travel plans in 25% of all travelers during travel and 21% after travel, which may 
have resulted in an adverse impact on their travel experience or work productivity. In 
addition, 7% of travelers reporting a health problem during travel saw a local doctor during 
travel and 1% were hospitalized, raising the concern for potential acquisition of nosocomial 
infections and colonization with multi-drug resistant (MDR) bacteria [12–17].
4.1. Potential improvements and interventions
We found that “unspecified chronic health conditions” were associated with health problems 
during travel, including hospitalization. Medical advances are enabling individuals with 
chronic and active medical problems opportunities to travel despite their health limitations 
[18,19]. Yet travelers with these problems may be more vulnerable to illness while traveling, 
possibly with increased susceptibility to infection, exposure to pathogens not present at 
home, and unfamiliar conditions or exertions due to travel, leading to exacerbation of their 
underlying conditions. This study underscores the need for more research into which chronic 
health conditions are actually associated with increased risk of encountering problems 
during travel, in addition to the need for individualized travel recommendations.
VFR travel has increased in proportion among U.S. travelers over time from 20% in 1995 up 
to 37% in 2014 [10], and some VFR travelers are at higher risk of certain travel-related 
illness such as hepatitis A, malaria, and typhoid fever [20–22]. Our analysis found similar 
rates of health problems between VFRs and tourist travelers, and no difference in influenza 
immunization rates between VFRs and non-VFRs. VFR travelers generally have been less 
likely to seek pre-travel advice than tourist travelers [22] and more likely to decline a 
recommended vaccine [23]. Our results suggest that VFR travelers who obtain pre-travel 
health consultation have similar rates of health problems as non-VFRs. Therefore, consistent 
messages from healthcare providers about travel-related health problems may encourage 
VFR travelers to obtain pre-travel health consultations.
Notably, travelers who received both influenza vaccination and influenza prevention advice 
reported lower rates of respiratory symptoms than those who received influenza prevention 
advice alone. This finding highlights the importance of tracking pre-travel consultation and 
intervention to health outcomes during and after travel, and systematic research regarding 
such a relationship is needed. As outlined in an Institute of Medicine report, international 
travel and commerce, human behavior, and demographics have been identified as major risk 
factors for the emergence of infectious diseases, including influenza [24]. Health 
professionals providing pre-travel consultation and interventions are well positioned to try to 
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influence the behavior of travelers to minimize health risks to themselves and the larger 
community. Moreover, our finding of increased respiratory symptoms with declining UN 
HDI appears plausible, although not previously emphasized [25], since countries with low 
UN HDI typically have suboptimal public health infrastructure, air quality, infectious disease 
surveillance, sanitation and infection control, and may experience emergence of new 
pathogens. Nevertheless, the specific relationships should be evaluated further. The potential 
for international travelers to disseminate microbes and resistance genes and contribute to the 
spread of emerging and re-emerging diseases are compelling reasons to promote pre-travel 
health consultations to advise travelers of this risk. Primary care and specialty providers are 
also positioned to educate patients about travel-related risk of influenza and antibiotic 
resistant organisms, especially for patients with chronic medical conditions.
4.2. Limitations
This study has the advantage over previous airport surveys and post-travel surveys in that a 
population was followed before, during, and after travel, but it has several limitations. 
BATMN sites may not be representative of traveler populations seen in other institutions or 
other geographic regions. Also, travelers who seek pre-travel consultation may not be 
representative of all travelers, and the difference in completion rates between sites and 
ethnicities may reflect biases among different groups. We were unable to determine whether 
travelers who developed illness during or after travel were more likely to complete the 
survey than those who remained well. Similar to other traveler surveys, the reporting of 
symptoms has inherent subjective biases. The sample size was relatively small, and a 
substantial proportion of participants did not complete a diary during travel or did not 
respond to requests to be interviewed post-travel. The category of travelers with “unspecified 
chronic health conditions” included diagnoses that did not fall into specific categories. The 
inclusiveness of this category limited the analysis on the association of chronic health 
conditions with travel-related health problems. We were unable to obtain information on the 
temperature of each traveler who reported fever during and/or after travel; therefore, cough 
and fever may not be suggestive of ILI. Because the post-travel survey was conducted 2–4 
weeks after travel, some reports of travel-associated ILI may have been overly inclusive. 
Also, symptoms such as fatigue and headache may be due to jet lag but we did not correlate 
these symptoms with time zones traveled. Education and advice given in different clinics 
may have varied in depth and quality. For example, details of the influenza prevention advice 
at different sites, such as hand-washing, were not captured and precluded assessment of 
whether such advice may be associated with reduced risk of respiratory and flu-like 
symptoms [26] as well as a reduced risk of gastrointestinal symptoms [27]. Of note, our 
study took place at the time of 2009 pandemic influenza A(H1N1) circulation. The 
discussion of influenza prevention, along with heightened awareness of influenza, may have 
led to beneficial behavior and outcomes.
Finally, this study did not explore the level of morbidity in those who do not seek pre-travel 
preparation, and cannot project morbidity for those travelers. Given the persistent travel-
related morbidity in those who received pre-travel preparation, new and more effective 
approaches are clearly needed to prevent travel-associated morbidity.
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5. Conclusions
Health problems during and after travel affected about two-thirds of international travelers 
who had received pre-travel consultation. Travelers primarily reported gastrointestinal, 
respiratory, and dermatologic symptoms and febrile illness. Disruption of travel plans results 
in inconvenience, stress, and a less enjoyable experience. Possible mitigation of respiratory 
illness by advice on influenza prevention and immunization would be a welcome benefit, but 
additional studies are needed to identify essential elements of the intervention. Preparing 
travelers to anticipate post-travel health problems is sensible. Behaviors such as hand 
washing could prevent other illnesses besides influenza or other respiratory infections. 
Future focus in travel medicine should address travelers with chronic illness by engaging 
their subspecialists and primary care doctors. Finally, immunizations must be combined with 
education about disease prevention due to a lack of vaccines to prevent some infections 
acquired by travelers, as well as incomplete protection provided by some vaccines, such as 
influenza.
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Figure 1. 
Study enrollment, those who completed all three data collection surveys, and those who 
reported health problems during and/or after travel.
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Figure 2. 
Impact of health problems experienced among those who reported health problems during (n 
=309) and after travel (n = 249).*
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Table 1
Demographics of participants (N = 628) and comparison between those reporting health problems during or 
after travel and those who did not experience health problems.
Total
N = 628
Reported
experiencing health
problem during and/or
after travel
N = 400
Did not experience
any health problems
during or after travel
N = 228
Median age, years (range) 47 (19–83) 47 (19–83) 48 (19–81)
Gender n (row %)
  Male 255 (41) 155 (61) 100 (39)
  Female 373 (59) 245 (66) 128 (34)
Duration of travel
  ≥14 days 238 (38) 163 (68) 75 (32)
  <14 days 383 (62) 233 (61) 150 (39)
Racea
  White 528 (85) 344 (65) 184 (35)
  Black 32 (5) 12 (38) 20 (63)
  Asian: Far East 28 (5) 18 (64) 10 (36)
  Asian: Indian Subcontinent 13 (2) 10 (77) 3 (23)
  Hispanic/Latino 10 (2) 5 (50) 5 (50)
  Bi/Multi-Racial 9 (2) 5 (56) 4 (44)
  Middle Eastern 2 (< 1) 1 (50) 1 (50)
Birth country
  U.S.-born 517 (82) 337 (65) 180 (35)
  Foreign-born 110 (18) 62 (56) 48 (44)
Travel reasonb
  Visiting friends and relatives (VFRs) 87 (14) 57 (66) 30 (34)
  Tourism/Vacation 419 (67) 269 (64) 150 (36)
  Business 115 (18) 75 (65) 40 (35)
  Educational/Research 24 (4) 18 (75) 6 (25)
  Volunteer/Missionary/Aid Work 97 (15) 58 (60) 39 (40)
  Seeking medical/dental care outside of the U.S. 1 (< 1) 0 (0) 1 (100)
  Other 14 (2) 10 (71) 4 (29)
Accommodationsb
  Hotel 412 (66) 269 (65) 143 (35)
  Home/Local Residence 127 (20) 85 (67) 42 (33)
  Hostel/Budget Hotel/Guest House 81 (13) 54 (67) 27 (33)
  Dormitory 28 (4) 15 (54) 13 (46)
  Tent 84 (13) 55 (65) 29 (35)
  Ship/Yacht/Boat 59 (9) 38 (64) 21 (36)
  Otherd 92 (15) 49 (53) 43 (47)
Top 5 destinationsb
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Total
N = 628
Reported
experiencing health
problem during and/or
after travel
N = 400
Did not experience
any health problems
during or after travel
N = 228
  India 107 (12) 70 (65) 37 (35)
  South Africa 46 (5) 20 (43) 26 (57)
  Tanzania 44 (5) 29 (66) 15 (34)
  Kenya 39 (4) 22 (56) 17 (44)
  Haiti 36 (4) 21 (58) 15 (42)
Destination grouping by UN Human Development Indexc
  Low human development 165 (26) 104 (63) 61 (37)
  Medium human development 320 (51) 209 (65) 111 (35)
  High human development 143 (23) 87 (61) 56 (39)
aNonwhites/whites PRR = 0.83, P = 0.04.
b
Respondents could have ≥1 choice.
c
Based on UN human development ranking (high + very high are combined); if traveler went to ≥1 country, the lowest ranked country was used.
dNo text specified.
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Table 3
Specific diagnoses and treatments received during travel or after travel.
Final diagnoses of those who saw a doctor because of health problems during travel (n = 21) n
Infectious = 7
  Amoebiasis 1
  Bacterial infection 1
  Cellulitis (left foot) 1
  Diarrhea 1
  Infection, influenza virus 1
  Streptococcal pharyngitis 1
  Upper respiratory infection 1
Injury = 3
  Broken toe, allergic reaction 1
  Fractured tibia (below knee) 1
  Laceration/sutures 1
Drug reaction = 2
  Reaction to transdermal scopolamine patch 2
Dermatologic = 2
  Frostbite 2+ degree 1
  Allergic reaction 1
No diagnosis specified = 7
Diagnoses given by physician or healthcare professional after travel – only for those who sought medical care from professionals (n = 52) n
Infectious = 26
  Sinusitis 5
  Cold/upper respiratory infection 4
  Virus 3
  Diarrhea 3
  Bronchitis 2
  Campylobacter 2
  Urinary tract infection 2
  Aseptic meningitis 1
  Bacteria 1
  Cellulitis 1
  Giardia 1
  Infected/fractured tooth 1
  Fever 1
  Ringworm 1
Injury = 2
  Fractured tooth 1
  X-ray ruled out fracture 1
Dermatologic = 4
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  Bites 2
  Allergic reaction 3
  Rash 1
Non-infectious respiratory problem = 2
  Pulmonary embolism 1
  Asthma attack 1
Ectopic pregnancy = 1
Other/unknown/missing (information included fever, bacteria, ruled out for malaria, ruled out for dengue, stool sample negative) = 17
Treatment prescribed or recommended reported after travel (n = 33)
  Over-the-counter medications 15
  Medications administered in-hospitala 6
  Herbal or holistic treatments 1
aOf six travelers who were given a medication while in a hospital, only one was hospitalized and reported a diagnosis of aseptic meningitis (given 
doxycycline). The other five travelers who received a medication in a hospital reported diagnoses and mediations as follows: (stomach virus, IV 
saline, 1 person); asthma attack, albuterol, 1); (ectopic pregnancy, methotrexate, 1); (sinusitis, ceftriaxone IV, 1); (cellulitis, IV antibiotics, 1).
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